Brokerages Set Harrow, Inc. (NASDAQ:HROW) Price Target at $71.43

Shares of Harrow, Inc. (NASDAQ:HROW) have been given an average rating of “Moderate Buy” by the ten ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $71.4286.

Several brokerages have recently issued reports on HROW. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. LADENBURG THALM/SH SH lifted their target price on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. HC Wainwright increased their price target on shares of Harrow from $64.00 to $69.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Zacks Research lowered shares of Harrow from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $94.00 price objective on shares of Harrow in a research report on Tuesday, November 11th.

Harrow Trading Up 1.9%

Shares of Harrow stock opened at $50.82 on Tuesday. The stock has a market cap of $1.88 billion, a PE ratio of -508.15 and a beta of 0.07. The firm has a fifty day moving average price of $47.63 and a 200 day moving average price of $42.78. Harrow has a 1 year low of $20.85 and a 1 year high of $54.85. The company has a debt-to-equity ratio of 5.21, a current ratio of 2.72 and a quick ratio of 2.52.

Institutional Trading of Harrow

Several institutional investors have recently bought and sold shares of HROW. Invesco Ltd. raised its stake in shares of Harrow by 35.7% during the 4th quarter. Invesco Ltd. now owns 145,406 shares of the company’s stock worth $7,125,000 after buying an additional 38,264 shares during the period. Occudo Quantitative Strategies LP purchased a new stake in Harrow in the 4th quarter worth $801,000. Cetera Investment Advisers raised its position in Harrow by 2.6% during the fourth quarter. Cetera Investment Advisers now owns 23,256 shares of the company’s stock worth $1,140,000 after acquiring an additional 597 shares during the period. Price T Rowe Associates Inc. MD raised its position in Harrow by 4.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,412 shares of the company’s stock worth $1,246,000 after acquiring an additional 1,161 shares during the period. Finally, Corsair Capital Management L.P. purchased a new position in Harrow during the fourth quarter valued at $490,000. 72.76% of the stock is owned by institutional investors and hedge funds.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.